DUX4L37: A Double Homeobox 4-like 37 (pseudogene) as a Drug Target and Biomarker

Target Name: DUX4L37

NCBI ID: G107080108

DUX4L37

Other Name(s): double homeobox 4 like 37 (pseudogene) | Double homeobox 4 like 37 (pseudogene)

DUX4L37: A Double Homeobox 4-like 37 (pseudogene) as a Drug Target and Biomarker

The double homeobox 4 (DHB4) gene is a key regulator of the stem-cell maintenance and proliferation, and is involved in various physiological processes, including tissue repair, regeneration, and development. Mutations in the DHB4 gene have been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Recent studies have identified a new variant of the DHB4 gene, named DUX4L37, which has unique properties that make it an attractive drug target and biomarker. In this article, we will explore the biology of DUX4L37 and its potential as a drug target and biomarker.

Biochemistry and Expression

DUX4L37 is a 21-kDa protein that contains 119 amino acid residues. It belongs to the homeobox gene family 4, which includes several similar proteins, including DUX4L36 and DUX4L38. These proteins are involved in the regulation of stem-cell proliferation and differentiation, and are considered potential drug targets for various diseases.

DUX4L37 was first identified by Southern blot analysis of DNA from human tissues, and its expression was verified by RT-PCR and immunofluorescence assays. DUX4L37 was shown to be expressed in various tissues and cells, including human brain, heart, liver, and cancer cells.

Function and Mechanisms

DUX4L37 is involved in the regulation of stem-cell proliferation and differentiation, as well as tissue repair and regeneration. It has been shown to play a role in the maintenance of stem-cell stem-like properties and its ability to differentiate into different cell types.

DUX4L37 is also involved in the regulation of cell adhesion and migration. It has been shown to promote the migration of cancer cells to new sites and is a potential therapeutic target for cancer.

DUX4L37 has been shown to play a role in the regulation of inflammation and cellular stress. It has been shown to contribute to the regulation of inflammation and cellular stress in response to various stimuli, including UV radiation, mechanical stress, and chemicals.

Drug Target Potential

DUX4L37 is a potential drug target due to its unique biology and the diseases it is involved in. Its role in the regulation of stem-cell proliferation and differentiation makes it a potential target for diseases associated with stem-cell dysfunction, such as cancer, neurodegenerative diseases, and developmental disorders.

DUX4L37 has also been shown to be involved in the regulation of inflammation and cellular stress, which makes it a potential target for diseases associated with inflammation and cellular stress, such as rheumatoid arthritis, osteoarthritis, and cancer.

Biomarker Potential

DUX4L37 has the potential to serve as a biomarker for various diseases. Its involvement in the regulation of stem-cell proliferation and differentiation makes it a potential biomarker for diseases associated with stem-cell dysfunction, such as cancer, neurodegenerative diseases, and developmental disorders.

DUX4L37 has also been shown to be involved in the regulation of inflammation and cellular stress, which makes it a potential biomarker for diseases associated with inflammation and cellular stress, such as rheumatoid arthritis, osteoarthritis, and cancer.

Conclusion

DUX4L37 is a unique protein that has been shown to play a role in the regulation of stem-cell proliferation and differentiation, as well as tissue repair

Protein Name: Double Homeobox 4 Like 37 (pseudogene)

The "DUX4L37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUX4L37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets